QUESTRAN Drug Patent Profile

When do Questran patents expire, and when can generic versions of Questran launch?

Questran is a drug marketed by Bristol Myers and Apothecon and is included in three NDAs.

The generic ingredient in QUESTRAN is cholestyramine. There are eight drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the cholestyramine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Questran

A generic version of QUESTRAN was approved as cholestyramine by EPIC PHARMA LLC on August 15^th, 1996.

Summary for QUESTRAN

US Patents:	0
Applicants:	2
NDAs:	3
Clinical Trials:	8
Formulation / Manufacturing:	see details
DailyMed Link:	QUESTRAN at DailyMed

Recent Clinical Trials for QUESTRAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	Phase 1
National Cancer Institute (NCI)	Phase 1
City of Hope Medical Center	Phase 2

See all QUESTRAN clinical trials

US Patents and Regulatory Information for QUESTRAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers	QUESTRAN	cholestyramine	POWDER;ORAL	016640-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Apothecon	QUESTRAN	cholestyramine	TABLET;ORAL	073403-002	Dec 27, 1999		DISCN	No	No
Bristol Myers	QUESTRAN	cholestyramine	POWDER;ORAL	016640-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Apothecon	QUESTRAN	cholestyramine	TABLET;ORAL	073403-001	Apr 28, 1994		DISCN	No	No
Bristol Myers	QUESTRAN LIGHT	cholestyramine	POWDER;ORAL	019669-003	Dec 5, 1988		DISCN	Yes	No
Bristol Myers	QUESTRAN LIGHT	cholestyramine	POWDER;ORAL	019669-001	Dec 5, 1988		DISCN	Yes	No